Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has struck agreements with two large animal health companies as it explores how its longevity research could be applied to pets.
The London-listed biotech, which is the only publicly quoted company in Europe focused on ageing, said it had signed confidentiality agreements that will allow it to share data and hold discussions about potential partnerships.
Genflow is developing a gene therapy based on a variant of the SIRT6 gene, which has been linked to longer life in humans who live to more than 100.
The company is already running a trial in beagles, known as the GF-1004 dog ageing study, and said no safety problems had been seen so far.
The talks are aimed at exploring whether the same technology could be used to extend the healthy lifespan of dogs and other companion animals.
Pet health has become a lucrative area for drugmakers in recent years, as owners spend more on treatments once reserved for people.
Eric Leire, Genflow’s chief executive, said: “The signing of these CDAs reflects strong industry interest in our longevity platform and represents a further step toward building strategic partnerships in animal health.
"As we continue to advance GF-1004 in our canine trial, engaging with major animal health players will strengthen our pathway to potential licensing agreements and future commercialisation.”
Genflow said working with a large pharmaceutical partner could help it bring its products to market more quickly by providing the regulatory know-how and sales networks it lacks on its own.